Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 3/20 | 0.52 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.52 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.37 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.37 |
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.37 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474446 | 0.99 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Methyl Alcohol SCHEMBL27751480 | 0.98 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27999217 | 0.88 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL31189348 | 0.84 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27829248 | 0.84 | PDE4D (0.41) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL28569717 | 0.84 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL23258348 | 0.83 | PDE3A (0.56) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL587469 | 0.82 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL587470 | 0.82 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27712544 | 0.82 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981267-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Bristol-Myers Squibb Company (US) | 2016-02-10 | — | — | EP | claimed |
| WO-2014165718-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | claimed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| CN-115103678-A | FGFR tyrosine kinase inhibitors for the treatment of high risk non-muscle invasive bladder cancer | 詹森药业有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115038466-A | Combination therapy and uses and methods thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114945386-A | Methods of treating diffuse large B-cell lymphoma using anti-CD 79B immunoconjugates | 基因泰克公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114222760-A | IL1RAP binding proteins | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112237631-B | Use of acetylcholine pathway modulators in the treatment of cancer | 清华大学 | 2022-03-04 | — | — | CN | disclosed |
| WO-2020044252-A1 | DOSAGE REGIMES FOR ANTI-M-CSF ANTIBODIES AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-05 | — | — | WO | disclosed |
| CN-109481691-A | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage | 珠海天香苑生物科技发展股份有限公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-102580084-B | The fixed dosage of HER antibody is administered | 健泰科生物技术公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20130078229-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | QUINTESSENCE BIOSCIENCES, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120276077-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8298801-B2 | Human ribonuclease for use in prevention and treatment of cancer; antitumor agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2010049947-A2 | PREPARATION OF GEMCITABINE AND INTERMEDIATES THEREOF | ACCRETE PHARMACEUTICAL PRIVATE LIMITED (IN) | 2010-05-06 | — | — | WO | disclosed |
| US-20100080789-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| EP-2094260-A1 | TREATMENT OF LUNG CANCER | Ramot at Tel-Aviv University Ltd. (IL) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075342-A1 | TREATMENT OF LUNG CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| US-20080095755-A1 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20050192247-A1 | Method of treating cancers | ARQULE, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192247-A1 | Method of treating cancers | CCNE1, CCNB1, CCNT1 | PDE3A 2143/4885PDE4D 3585/4885CACNA1F 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.